APA (7th ed.) Citation

JH, W., AD, S., S, B., P, S., N, R., RM, P., . . . AP, K. (2025). Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(18), 2059. https://doi.org/10.1200/JCO-25-00131

Chicago Style (17th ed.) Citation

JH, Wang, et al. "Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 43, no. 18 (2025): 2059. https://doi.org/10.1200/JCO-25-00131.

MLA (9th ed.) Citation

JH, Wang, et al. "Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 43, no. 18, 2025, p. 2059, https://doi.org/10.1200/JCO-25-00131.